GLP-1 Drugs Added to Standard PCOS Treatment Outperform Standard Therapy Alone for Weight and Metabolic Health

Systematic review and network meta-analysis of 29 randomized controlled trials including 1,476 women with PCOS. Researchers searched PubMed, MEDLINE, Embase, and Web of Science through October 2023. Only RCTs with at least 12 weeks of follow-up were included. Outcomes measured included body weight, BMI, waist circumference, testosterone, SHBG, lipid profiles, HOMA-IR, fasting glucose, and fasting insulin. Network meta-analysis allowed indirect comparison between treatments that hadn't been studied head-to-head.

PCOS affects up to 13% of women of reproductive age and involves a tangled web of metabolic and hormonal problems — insulin resistance, excess androgens, weight gain, and cardiovascular risk. This meta-analysis provides the strongest evidence to date that GLP-1 drugs, already transforming obesity and diabetes care, can be a powerful addition to PCOS treatment by addressing the metabolic component.

GLP-1 drugs are rapidly expanding beyond diabetes and obesity into other conditions where metabolic dysfunction plays a central role. PCOS is a prime candidate because insulin resistance drives many of its symptoms. This meta-analysis provides the highest level of evidence yet supporting GLP-1 agonists as part of PCOS management, and may influence clinical guidelines as the data accumulates.

The 29 included trials varied in specific GLP-1 drugs used, doses, and definitions of standard therapy. With 1,476 total participants spread across multiple comparison arms, individual comparisons may be underpowered. Most trials had 12-week minimum follow-up, so long-term effects and sustainability of improvements are unknown. The analysis could not evaluate fertility outcomes or menstrual regularity.